Publicaciones en colaboración con investigadores/as de University of Antwerp (34)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  3. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 51, Núm. 9, pp. 2706-2732

  4. Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines

    European Journal of Nuclear Medicine and Molecular Imaging

  5. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Annals of Oncology, Vol. 35, Núm. 11, pp. 981-992

  6. Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer–a plain language summary

    Future Oncology, Vol. 20, Núm. 22, pp. 1531-1544

  7. Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy

    European Journal of Cancer, Vol. 208

  8. Treatment and outcomes in breast cancer patients: A cross section study from the EUSOMA breast centre network

    European Journal of Cancer, Vol. 196

2023

  1. Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

    Cells, Vol. 12, Núm. 15

  2. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer

    European Journal of Cancer, Vol. 189

  3. Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

    Gynecologic Oncology, Vol. 170, pp. 300-308

  4. Trends and variation in treatment of early breast cancer in European certified breast centres: an EUSOMA-based analysis

    European Journal of Cancer, Vol. 192

  5. Uncertainties and controversies in axillary management of patients with breast cancer

    Cancer Treatment Reviews, Vol. 117

2022

  1. Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

    Gynecologic Oncology, Vol. 166, Núm. 1, pp. 36-43

  2. Impact of COVID-19 Lockdown in Eating Disorders: A Multicentre Collaborative International Study

    Nutrients, Vol. 14, Núm. 1

  3. Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy

    Breast, Vol. 63, pp. 123-139

  4. The impact of the SARS-COV-2 pandemic on the quality of breast cancer care in EUSOMA-certified breast centres

    European Journal of Cancer, Vol. 177, pp. 72-79

2021

  1. Additional causal SNRPE mutations in hereditary hypotrichosis simplex

    British Journal of Dermatology

  2. Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox

    The Lancet Oncology, Vol. 22, Núm. 1, pp. e18-e28

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382